Probiodrug announces completion of recruitment for the SAPHIR Phase 2a study of Glutaminyl Cyclase Inhibitor PQ912 in early Alzheimer's disease patients
HALLE (SAALE), Germany, 09 January 2017 - Probiod [...]
Final panel demonstrates overall weighted average sensitivity of 91.4% and overall weighted average specificity of 99.5% across all lower respiratory tract panel pathogens
Unyvero results available after app [...]
UTRECHT, The Netherlands, Jan. 05, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, and the Institute for Research in [...]
Highly multiplexed panel covers up to 112 diagnostic targets
Third new panel developed within one year after IPO
Amsterdam, the Netherlands, and Holzgerlingen, Germany, January 04, 2017 - Cureti [...]
Agreement Brings Together MD Anderson's Natural Killer Cell and Affimed's Antibody-based Technologies
Heidelberg, Germany and Houston, January 4, 2017 - Affimed N.V. (Nasdaq: AFMD), a clinical stage b [...]
Probiodrug announces completion of recruitment for the SAPHIR Phase 2a study of Glutaminyl Cyclase Inhibitor PQ912 in early Alzheimer's disease patients
HALLE (SAALE), Germany, 09 January 2017 - Probiod [...]
Final panel demonstrates overall weighted average sensitivity of 91.4% and overall weighted average specificity of 99.5% across all lower respiratory tract panel pathogens
Unyvero results available after app [...]
UTRECHT, The Netherlands, Jan. 05, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, and the Institute for Research in [...]
Highly multiplexed panel covers up to 112 diagnostic targets
Third new panel developed within one year after IPO
Amsterdam, the Netherlands, and Holzgerlingen, Germany, January 04, 2017 - Cureti [...]
Agreement Brings Together MD Anderson's Natural Killer Cell and Affimed's Antibody-based Technologies
Heidelberg, Germany and Houston, January 4, 2017 - Affimed N.V. (Nasdaq: AFMD), a clinical stage b [...]
Follow us
